High-Cost Blood Cancer Drugs Deliver High Value

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.

Researchers present this viewpoint, based upon a comprehensive analysis of published cost-effectiveness ratios, online today in Blood, the Journal of the American Society of Hematology. The manuscript is being published as a Blood Forum article, a feature of the journal designed to present well-documented opinions on controversial topics and provide a sounding board for issues of importance to the science and practice of hematology.

Read the press release from the American Society of Hematology: http://bit.ly/1CCdkzH